Key result
Low von Willebrand factor (30-50 IU/dL) is a complex disorder with variable bleeding phenotypes, reduced VWF biosynthesis, and enhanced clearance, distinct from type 1 VWD.
Why the study?
Management of patients with mild to moderate VWF reductions between 30 and 50 IU/dL is challenging, as bleeding phenotypes vary and pathogenesis remains incompletely understood.
Low von Willebrand factor is a complex disorder that falls between type 1 VWD and bleeding disorders of unknown cause, often requiring hemostatic treatment like tranexamic acid or desmopressin prior to elective procedures.
Answers are grounded in this paper and cite their sources.
Bleeding risk stratification in low VWF remains unreliable; leaves open identification of phenotypic modifiers for future studies.
Abstract von Willebrand disease (VWD) represents the most common inherited bleeding disorder. The majority of VWD cases are characterized by partial quantitative reductions in plasma von Willebrand factor (VWF) levels. Management of patients with mild to moderate VWF reductions in the range of 30 to 50 IU/dL poses a common clinical challenge. Some of these low VWF patients present with significant bleeding problems. In particular, heavy menstrual bleeding and postpartum hemorrhage can cause significant morbidity. Conversely, however, many individuals with mild plasma VWF:Ag reductions do not have any bleeding sequelae. In contrast to type 1 VWD, most patients with low VWF do not have detectable pathogenic VWF sequence variants, and bleeding phenotype correlates poorly with residual VWF levels. These observations suggest that low VWF is a complex disorder caused by variants in other genes beyond VWF. With respect to low VWF pathobiology, recent studies have shown that reduced VWF biosynthesis within endothelial cells likely plays a key role. However, pathological enhanced VWF clearance from plasma has also been described in approximately 20% of low VWF cases. For low VWF patients who require hemostatic treatment prior to elective procedures, tranexamic acid and desmopressin have both been shown to be efficacious. In this article, we review the current state of the art regarding low VWF. In addition, we consider how low VWF represents an entity that appears to fall between type 1 VWD on the one hand and bleeding disorders of unknown cause on the other.
No takes yet. Share an insight, caveat, or question.
O’Donnell et al. (2023) conducted a review in Low von Willebrand Disease. Low von Willebrand factor (VWF) levels was evaluated. Low von Willebrand factor (30-50 IU/dL) is a complex disorder with variable bleeding phenotypes, reduced VWF biosynthesis, and enhanced clearance, distinct from type 1 VWD.
Synapse has enriched 10 related papers. Consider them for comparative context: